Anorexia - Pipeline Insight, 2022

DelveInsight’s, “Anorexia – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anorexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Anorexia Understanding
Anorexia: Overview
Anorexia Nervosa is a serious eating disorder that is treatable but can be life-threatening without intervention. With over 200,000 individuals in the United States impacted per year and the highest mortality rate of any mental illness, it is important to learn the signs, symptoms, and treatment options for this disorder. Anorexia Nervosa is characterized by the National Institute of Mental Illness as individuals that have “a significant and persistent reduction in food intake leading to extremely low body weight; a relentless pursuit of thinness; a distortion of body image and intense fear of gaining weight; and extremely disturbed eating behavior. Anorexia has no single cause. it seems that a genetic predisposition is necessary but not sufficient for development of the disorder. A positive diagnosis of psychologically driven weight loss can be made in most patients, without the need for a battery of complex investigations to reach a diagnosis of exclusion. Basic medical investigations, blood tests, electrocardiography, weighing, and measuring the patient provide an opportunity for the patient to return (to discuss the results) and can uncover psychological problems.
Strategies include:
cognitive-behavioral therapy (CBT), which can help the person find new ways of thinking, behaving, and managing stress
family and individual counseling, as appropriate
nutritional therapy, which provides information on how to use food to build and maintain health
medication to treat depression and anxiety
supplements to resolve nutritional deficiencies
hospital treatment, in some cases

Anorexia Emerging Drugs Chapters
This segment of the Anorexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anorexia Emerging Drugs
ART2713: Artelo Biosciences
ART27.13 is a dual agonist program targeting cancer, cancer-related anorexia and weight loss. It is a clinic-ready, potent, peripherally restricted CB1/CB2 synthetic agonist. Existing clinical data with ART27.13 suggests meaningful potential for the treatment of cancer-related anorexia and weight loss (cachexia). In five Phases I clinical studies including over 200 subjects, ART27.13 demonstrated a statistically significant and dose-proportional increase in body weight. In ongoing consultation with regulatory authorities, we plan to advance ART27.13 as a multi-modal supportive care therapy for cancer patients suffering from anorexia or weight loss. Numerous non-peripherally restricted CB1 and CB2 agonists have shown promising results as anti-tumor drugs, yet their profile made them unsuitable for further development. It is currently in Phase I/II stage of development for Anorexia and is being developed by Artelo Biosciences in collaboration with AstraZeneca.
Further product details are provided in the report……..

Anorexia: Therapeutic Assessment
This segment of the report provides insights about the different Anorexia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Anorexia
There are approx. 5+ key companies which are developing the therapies for Anorexia. The companies which have their Anorexia drug candidates in the mid to advanced stage, i.e. Phase I/II include, Artelo Biosciences.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Late-stage products (Phase III )
Mid-Stage products (Phase II)
Early-stage products ( Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Anorexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Oral
Molecule Type

Products have been categorized under various Molecule types such as
Small molecules
Peptide
Antibiotics
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anorexia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anorexia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anorexia drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Anorexia R&D. The therapies under development are focused on novel approaches to treat/improve Anorexia.
Anorexia Report Insights
Anorexia Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Anorexia Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Anorexia drugs?
How many Anorexia drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anorexia?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anorexia therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Anorexia and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Amgen
COMPASS Pathways
Benuvia Therapeutics
Artelo Biosciences
RaQualia Pharma
Receptor Life Sciences
Pfizer

Key Products
Romosozumab
Psilocybin
RQ 00433412
ART 2713
PF-07258669

Companies

Amgen
COMPASS Pathways
Benuvia Therapeutics
Artelo Biosciences
RaQualia Pharma
Receptor Life Sciences
Pfizer